Physician profile
Christine Pocha
NPI 1043228745
$69,720.89
in general payments reported to CMS, 2019-2025
10 companies · $27K in 2025
The $27K reported for 2025 was more than what 96% of Transplant Surgery providers received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.70 · 2021: $120 · 2022: $364 · 2023: $12K · 2024: $31K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Travel and Lodging: $9,845 · Food and Beverage: $6,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,286.00 |
| Travel and Lodging | $9,844.73 |
| Food and Beverage | $6,014.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $33,468.91 | 2019-2025 | Epclusa, Livdelzi |
| Madrigal Pharmaceuticals | $21,521.79 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $9,154.86 | 2025 | Iqirvo |
| Boston Scientific Corporation | $4,996.91 | 2024-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Novo Nordisk INC | $199.74 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $118.45 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
| Mallinckrodt Hospital Products INC. | $79.72 | 2025 | Terlivaz |
| Abbvie INC. | $62.81 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Pocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.